Safety considerations in pharmacotherapy of bipolar disorder

CNS Spectrums

Volumn 9, Issue 11 SUPPL. 12, 2004, Pages 16-26

  Masand, Prakash S ^a   Fazal, Farhan S ^b   Patkar, Ashwin A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE; ZONISAMIDE;

AGRANULOCYTOSIS; AKATHISIA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; BIPOLAR DISORDER; BLOOD DYSCRASIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONFERENCE PAPER; DIABETES INSIPIDUS; DIABETIC KETOACIDOSIS; DIARRHEA; DISABILITY; DIZZINESS; DRUG CLASSIFICATION; DRUG INDICATION; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSTONIA; EDEMA; ENZYME INDUCTION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HAIR LOSS; HEADACHE; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPEROSMOLAR COMA; HYPERPROLACTINEMIA; HYPONATREMIA; HYPOTHYROIDISM; INSOMNIA; LANGUAGE DISABILITY; LETHARGY; LITHIUM BLOOD LEVEL; LIVER FAILURE; MEMORY DISORDER; META ANALYSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NEURAL TUBE DEFECT; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PARESTHESIA; POLYURIA; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RASH; RELAPSE; SEDATION; SHORT TERM MEMORY; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT PLANNING; TREMOR; WEIGHT GAIN;

EID: 9744221195     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900028856     Document Type: Conference Paper

References (84)

1. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990.
2. Murray CL, Lopez AD, eds. The Global Burden of Disease. Boston, Mass: Harvard University Press; 1996.
3. Osby U, Brandt L, Correla N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850.
4. Simon GE. Social and economic burden of mood disorders. Biol Psychiatry. 2003;54:208-215.
5. Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of literature. J Clin Psychopharmacol. 1992;12(4):276-281.
6. Maj M. The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence. Bipolar Disord. 2000;2:93-101.
7. Moller HJ, Nasrallah HA. Treatment of bipolar disorder. J Clin Psychiatry. 2003;64(Suppl 6):9-17.
8. Tohen M, Jacobs TG, Grundy SL, et al; The olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57:841-849.
9. Dube S, Anderson SE, Sanger TM, et al. Olanzapine-fluoxetine combination for psychotic major depression. Poster presented at: Annual meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, PA.
10. Vieta E, Brugue E, Goikolea JM, et al. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol. 2004;19:41-45.
11. Bowden CL, Brugger AM, Swann AC, et al. The Depakote Mania Study Group. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271:918-924.
12. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar 1 depression. J Clin Psychiatry. 1999;60:79-88.
13. McElroy SL, Keck PE Jr. Pharmacological agents for the treatment of acute bipolar mania. Biol Psychiatry. 2000;48:539-557.
14. Weisler RH, Kalali AH, Ketter TA, and the SPD417 Study Group. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. In press.
15. Ketter TA, Kalali AH, Weisler RH, and the SPD417 Study Group. A 6-month, multicenter, open-label evaluation of extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. In press.
16. Shire Pharmaceutical Development Inc. Data on file. Study 304, 2003.
17. Marcotte D. Use of topiramate, a new antiepileptic, as a mood stabilizer. J Affect Disord. 1998;50:245-251.
18. Baldassano CF, Ghaemi SN, Ballas C, et al. Adjunctive zonisamide as immediate treatment of bipolar disorder outpatients. Poster presented at: annual meeting of American Epilepsy Society; December 6-11, 2002; Seattle, WA.
19. Silverstone PH, Silverstone T. A review of acute treatments for bipolar depression. Int Clin Pychopharmacol. 2004;19(3):113-124.
20. Parker G, Parker K. Which antidepressants flick the switch? Aust N Z J Psychiatry. 2003;37(4):464-468.
21. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161-174.
22. Nasrallah HA. Factors in antipsychotic drug selection: tolerability considerations. CNS Spectr. 2003;8(11 Suppl 2):23-25.
23. Bendz H, Aurell M. Adverse affects of lithium treatment and safety routines. Lakartidningen. 2004;101(21-22):1902-1906,1908.
24. Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs. 2002;16(11):721-729.
25. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J Pharm Technol. 1995;11(2):55-59.
26. Ebert MH, Loosen PT, Nurcombe B. Bipolar disorder: Current Diagnosis & Treatment in Psychiatry. E-Book. New York, NY: McGraw Hill Companies; Copyright © 2002-2003.
27. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitude toward lithium: relationship to compliance. Arch Gen Psychiatry. 1979;36:866-869.
28. Baptista T, Teneud L, Contreras Q, et al. Lithium and body weight gain. Pharmacopsychiatry. 1995;28(2):35-34.
29. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar 1 disorder. J Clin Psychiatry. 2003;64(9):1013-1024.
30. Bowden CL. Valproate. Bipolar Disord. 2003;5:189-202.
31. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990;147(4):431-434.
32. Depakon® [package insert]. North Chicago, Il: Abbott laboratories; 2000.
33. Macritchie K, Geddes JR, Scott J, et al. Valproate (Cochrane review). Issue 4. 2004.
34. Holtmann M, Krause M, Opp J, et al. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children. Neuropediatrics. 2002;33:298-300.
35. Ghaemi SN, Berv DA, Klugman J et al. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry. 2003;64(8):943-945.
36. Mendlewicz J, Souery D, Rivelli SK. Short-term and long-term treatment for bipolar patients: beyond the guidelines. J Affect Disord. 1999;55:79-85.
37. Tegretol® [package insert]: East Hanover, NJ: Novartis Pharmaceuticals Corp; 2001.
38. Freeman MP, Stoll AL. Mood stabilizer combination: a review of safety and efficacy. Am J Psychiatry. 1998;155(1):12-21.
39. Bowden CL, Asnis GM, Ginsberg LD, et al. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf. 2004;27(3):173-184.
40. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: a review of its use in bipolar disorder. Drugs. 2003;63(19):2029-2050.
41. Biton V, Mitza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56(2):172-177.
42. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar 1 disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57(5):490-492.
43. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry. 2003;64(5):532-539.
44. Suppes T. Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol. 2002;22(6):599-609.
45. McElroy SL, Suppes T, Keck PE Jr, et al. Open-label adjunctive to topiramate in the treatment of bipolar disorders. Biol Psychiatry. 2000;47(12):1025-1033.
46. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520.
47. Keck PE Jr, Marcus R, Tourkodimitris S, et al; Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
48. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(Suppl 9):16-20.
49. Kane JM, Woemer M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull. 1986;22:254-258.
50. Yassa R, Nair NP. A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand. 1992;86:262-266.
51. Hunt N, Silverstone T. Tardive dyskinesia in bipolar affective disorder: a catchment area study. Int Clin Psychopharmacol. 1991;6:45-50.
52. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriartric Soc. 1999;47:716-719.
53. Zhang XY, Zhou DF, Cao Ly, et al. The effect of vitamin E treatment on terdive dyskinesia and blood superoxide dismutase: A double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2004;1:83-86.
54. Lerner V, Miodownick C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158(9):1511-1514.
55. Mokdad AH, Bowman BA, Ford FS, et al. The continuing epidemics of obesity and diabetes in United States. JAMA. 2001;286:1195-1200.
56. National Task Force on the Prevention and Treatment of Obesity. JAMA. 1996;276:1907-1915.
57. Carek PJ, Sherer JT, Carson DS. Management of obesity: medical treatment options. Am Fam Physician. 1997;55:551-562.
58. Elmslie JL, Silverstone JT, Mann JI, et al. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;61(3):179-184.
59. Masand P, Gupta S. Quality of life issues associated with antipsychotic-induced weight gain. Expert Rev. Pharmacoeconomics Outcomes Res. 2003;3(5):651-659.
60. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
61. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of mood stabilizer with risperidone or haloperidol for treatment of acute mania: a doubleblind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159(7):1146-1154.
62. Marcus RN, Carson WH Jr, McQuade RD, et al. Overview of safety and tolerability of aripiprazole in acute mania. Poster presented at: 157th Annual Meeting of American Psychiatric Association; May 1-6, 2004; New York, NY.
63. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62-69.
64. Vieta E, Sanchez-Moreno J, Golkelia JM, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol. 2004;24(4):374-378.
65. Keck PE, Potkin SG, Giller E Jr, et al. Ziprasidone's long-term efficacy and safety in bipolar disorder. Poster presented at: 157th Annual Meeting of American Psychiatric Association; May 1-6, 2004; New York, NY.
66. Caballero E. Obesity, diabetes, and the metabolic syndrome: New challenges in antipsychotic drug therapy. CNS Spectr. 2003;8(11 Suppl 2):19-22.
67. Merz CN, Buse JB, Tuncer D, Twillman GB. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol. 2002;40:1877-1881.
68. Brown WV. Risk factors for vascular disease in patients with diabetes. Diabetes Obes Metab. 2000;2(Suppl):S11-S18.
69. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-486.
70. Ryall RW. Some actions of chlorpromazine. Br J Pharmacol. 1956;11(3):339-345.
71. Gupta S, Lentz B, Lockwood K, et al. Atypical antipsychotics and glucose dysregulation: a series of 4 cases. Prim Care Companion J Clin Psychiatry. 2001;3(2):61-65.
72. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41(3):337-343.
73. Glick ID, Romano SJ, Simpson G, et al. Insulin resistance in olanzapine and ziprasidone treated patients: results of a double-blind, controlled 6-week trial. Poster presented at: 154th Annual Meeting of the American Psychiatric association; May 7-11, 2001; New Orleans, La.
74. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004;65(6):587-863.
75. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735-744.
76. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-852.
77. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical and atypical antipsychotics. Am J Psychiatry. 2003;160:290-296.
78. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
79. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry. 2003;182:199-204.
80. Keck PE Jr, Sanchez R, Marcus RN, et al. Aripiprazole for relapse prevention in bipolar disorder in 26-week trial. Poster presented at: 157th Annual Meeting of American Psychiatric Association; May 1-6, 2004; New York, NY.
81. Hennessy S, Bilker WB, Santanna JC, et al. Cardiac arrest risk appears to vary little by choice of antipsychotic drug. Poster presented at: Annual Meeting of American Psychiatric Association; May 7-11, 2001; New Orleans, La.
82. FDA Psychopharmacological Drug Advisory Committee. Pfizer study 54. July 19, 2000.
83. Funck-Brentano C, Jailon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol. 1993;72:178-228.
84. Gupta S, Masand PS, Gupta S. Cardiovascular side effects of novel antipsychotics. CNS Spectr. 2001;6(11):912-918.